- cafead Jan 11, 2022 at 10:22: PM
via Sanofi has been no stranger to the biopharma dealmaking circuit under CEO Paul Hudson, and last year it inked a handful of biotech buyouts for mRNA, an FDA-approved transplant med and more. But Sanofi's busy 2021 doesn't mean the company will shy away from potential future deals, its CFO said.
article source
article source